Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05631327 · ClinicalTrials.gov registry record · Phase 1
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05631327 is a Phase 1 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 12 participants.
The verdict
NCT05631327, a Phase 1 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of JZP341 in participants with advanced or metastatic solid tumors.
Interventions
- DRUG JZP341
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-12-19 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05631327
The ClinicalTrials.gov registry entry for NCT05631327 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JZP341 is the first listed.
NCT05631327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05631327 about?
NCT05631327 is a clinical study titled "A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors". This study will assess the safety and efficacy of JZP341 in participants with advanced or metastatic solid tumors.
What is the current status of trial NCT05631327?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-12-19. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT05631327?
The interventions under investigation include: JZP341 (DRUG).
Who is sponsoring clinical trial NCT05631327?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.